

Mumbai, 13th August, 2021

RDIF and Wockhardt partner to produce Sputnik V and Sputnik Light vaccines against COVID-19

The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Wockhardt Limited, a global pharmaceutical company headquartered in India, have partnered to produce and supply Sputnik V and Sputnik Light vaccines against COVID-19. The agreement was reached under the aegis of Enso Healthcare (part of Enso Group), RDIF's coordination partner for sourcing Sputnik V vaccines in India.

To date, the Sputnik V vaccine has been registered in 69 countries globally with a total population of over 3.7 billion people. The data obtained by regulators of a number of countries during the vaccination of the population, including Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.

In particular, Sputnik V demonstrates 83.1% efficacy against the Delta variant of coronavirus - higher than many other vaccines. The vaccine shows 6 times reduction of infection risk. Sputnik V is also 94.4% effective against hospitalisations with 18 times reduction in hospitalisation risk.

Sputnik V is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

Sputnik Light is the first component of Sputnik V and is based on human adenovirus serotype 26.

Dr. Habil Khorakiwala, Founder Chairman of Wockhardt Group, said: "We are delighted to partner with RDIF to make a substantial contribution towards providing global supply of the Sputnik V and Sputnik Light vaccines which is one of the most efficacious approved vaccines commercially available. The arrangement upholds our ongoing commitment to fight against such a pandemic of global human importance."

Vinay Maloo, Chairman of Enso Healthcare, said: "It is our privilege to partner with RDIF and Wockhardt to facilitate large scale manufacturing of Sputnik V and Sputnik Light vaccines. Vaccinations are the most visible solution to this pandemic. We are proud to be a part of this noble cause. Sputnik V is known to have high efficacy and has emerged as a trusted vaccine."

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF's management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totalling RUB 2.1 trillion and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 1 million people and generate revenues which equate to more than 6% of Russia's GDP. RDIF has established joint strategic partnerships with leading international co-investors from over 18 countries that total more than \$40 billion. Further information can be found at rdif.ru

Wockhardt Limited is a global pharmaceutical and biotechnology company headquartered in India. The company provides affordable, high-quality medicines through its manufacturing plants in India, UK, Ireland and US. More than 80% of Wockhardt's revenue comes from international business. For more information visit www.wockhardt.com

For further information, please contact:

RDIF contact

Alexey Urazov
Director for External Communications
Mobile: +7 915 312 76 65
E-mail: Alexey.Urazov@rdif.ru

Wockhardt contact

Ankeet Doshi
Head - Corporate Strategy, Business Development and M&A
Email: adoshi@wockhardt.com